4170
Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It is involved in cell preparation product manufacturing; and collection and storage of immune cells. The company's products are used in the field of infectious diseases and inflammation, cancer, oncology. Vectorite Biomedical Inc. was incorporated in 2004 and is based in New Taipei C… Read more
4170 (4170) - Net Assets
Latest net assets as of June 2025: NT$393.46 Million TWD
Based on the latest financial reports, 4170 (4170) has net assets worth NT$393.46 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$417.08 Million) and total liabilities (NT$23.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$393.46 Million |
| % of Total Assets | 94.34% |
| Annual Growth Rate | 2.75% |
| 5-Year Change | 12.89% |
| 10-Year Change | N/A |
| Growth Volatility | 16.14 |
4170 - Net Assets Trend (2019–2024)
This chart illustrates how 4170's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 4170 (2019–2024)
The table below shows the annual net assets of 4170 from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$389.58 Million | -9.58% |
| 2023-12-31 | NT$430.85 Million | -2.38% |
| 2022-12-31 | NT$441.34 Million | -5.48% |
| 2021-12-31 | NT$466.94 Million | +35.31% |
| 2020-12-31 | NT$345.08 Million | +1.46% |
| 2019-12-31 | NT$340.13 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 4170's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 21115900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$437.71 Million | 112.48% |
| Other Comprehensive Income | NT$-13.56 Million | -3.49% |
| Other Components | NT$11.67 Million | 3.00% |
| Total Equity | NT$389.16 Million | 100.00% |
4170 Competitors by Market Cap
The table below lists competitors of 4170 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Associated Industries China Inc
TW:9912
|
$13.25 Million |
|
Dongil Metal Co. Ltd
KQ:109860
|
$13.26 Million |
|
BCM Resources Corporation
PINK:BCMRF
|
$13.26 Million |
|
HEBEI CONSTR.GRP CORP YC1
F:H9D
|
$13.26 Million |
|
GENOMTEC S.A. ZY -10
F:4VI
|
$13.24 Million |
|
Koil Energy Solutions Inc.
OTCQB:KLNG
|
$13.24 Million |
|
Netgem SA
PA:ALNTG
|
$13.24 Million |
|
SOSANDAR PLC LS -001
F:HXKB
|
$13.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 4170's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 430,441,000 to 389,163,000, a change of -41,278,000 (-9.6%).
- Net loss of 40,052,000 reduced equity.
- Other comprehensive income decreased equity by 1,225,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-40.05 Million | -10.29% |
| Other Comprehensive Income | NT$-1.23 Million | -0.32% |
| Other Changes | NT$-1.00 | -0.0% |
| Total Change | NT$- | -9.59% |
Book Value vs Market Value Analysis
This analysis compares 4170's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.98x to 1.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$6.78 | NT$13.40 | x |
| 2020-12-31 | NT$11.79 | NT$13.40 | x |
| 2021-12-31 | NT$12.78 | NT$13.40 | x |
| 2022-12-31 | NT$10.07 | NT$13.40 | x |
| 2023-12-31 | NT$9.83 | NT$13.40 | x |
| 2024-12-31 | NT$8.90 | NT$13.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 4170 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -69.33%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.06x
- Recent ROE (-10.29%) is above the historical average (-11.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -31.59% | -340.11% | 0.07x | 1.36x | NT$-118.84 Million |
| 2020 | -19.78% | -277.75% | 0.07x | 1.07x | NT$-102.63 Million |
| 2021 | 1.79% | 29.05% | 0.06x | 1.06x | NT$-38.29 Million |
| 2022 | -5.99% | -61.55% | 0.09x | 1.06x | NT$-70.50 Million |
| 2023 | -1.53% | -11.82% | 0.12x | 1.05x | NT$-49.65 Million |
| 2024 | -10.29% | -69.33% | 0.14x | 1.06x | NT$-78.97 Million |
Industry Comparison
This section compares 4170's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 4170 (4170) | NT$393.46 Million | -31.59% | 0.06x | $13.25 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |